End-of-day quote
Korea S.E.
06:00:00 2024-06-25 pm EDT
|
5-day change
|
1st Jan Change
|
11,880
KRW
|
+0.08%
|
|
-0.17%
|
-7.69%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
347,568
|
313,524
|
328,567
|
214,461
|
188,137
|
199,286
|
Enterprise Value (EV)
1 |
389,821
|
348,370
|
362,512
|
255,871
|
226,460
|
217,251
|
P/E ratio
|
22
x
|
14.3
x
|
19
x
|
16.7
x
|
12.6
x
|
7.08
x
|
Yield
|
2.28%
|
2.53%
|
2.41%
|
3.61%
|
4.12%
|
3.89%
|
Capitalization / Revenue
|
2.24
x
|
1.84
x
|
1.79
x
|
1.26
x
|
1
x
|
0.96
x
|
EV / Revenue
|
2.51
x
|
2.05
x
|
1.98
x
|
1.51
x
|
1.2
x
|
1.05
x
|
EV / EBITDA
|
11.3
x
|
8.42
x
|
7.01
x
|
6.14
x
|
5.39
x
|
4.68
x
|
EV / FCF
|
17.3
x
|
23.2
x
|
16.6
x
|
24.9
x
|
26
x
|
8.11
x
|
FCF Yield
|
5.79%
|
4.32%
|
6.01%
|
4.01%
|
3.85%
|
12.3%
|
Price to Book
|
3.18
x
|
2.56
x
|
2.48
x
|
1.63
x
|
1.34
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
15,835
|
15,835
|
15,835
|
15,485
|
15,485
|
15,485
|
Reference price
2 |
21,950
|
19,800
|
20,750
|
13,850
|
12,150
|
12,870
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/25/21
|
3/28/22
|
3/21/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
155,230
|
170,221
|
183,521
|
169,817
|
188,931
|
206,860
|
EBITDA
1 |
34,640
|
41,375
|
51,697
|
41,661
|
42,045
|
46,393
|
EBIT
1 |
23,541
|
29,749
|
39,451
|
28,417
|
27,089
|
30,862
|
Operating Margin
|
15.17%
|
17.48%
|
21.5%
|
16.73%
|
14.34%
|
14.92%
|
Earnings before Tax (EBT)
1 |
21,311
|
28,331
|
22,740
|
18,287
|
20,782
|
33,708
|
Net income
1 |
15,821
|
21,938
|
17,300
|
12,914
|
14,961
|
28,144
|
Net margin
|
10.19%
|
12.89%
|
9.43%
|
7.6%
|
7.92%
|
13.61%
|
EPS
2 |
999.1
|
1,385
|
1,093
|
828.8
|
966.0
|
1,818
|
Free Cash Flow
1 |
22,573
|
15,043
|
21,798
|
10,273
|
8,717
|
26,784
|
FCF margin
|
14.54%
|
8.84%
|
11.88%
|
6.05%
|
4.61%
|
12.95%
|
FCF Conversion (EBITDA)
|
65.17%
|
36.36%
|
42.16%
|
24.66%
|
20.73%
|
57.73%
|
FCF Conversion (Net income)
|
142.68%
|
68.57%
|
126%
|
79.55%
|
58.26%
|
95.17%
|
Dividend per Share
2 |
500.0
|
500.0
|
500.0
|
500.0
|
500.0
|
500.0
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/25/21
|
3/28/22
|
3/21/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
42,253
|
34,846
|
33,945
|
41,410
|
38,322
|
17,965
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.22
x
|
0.8422
x
|
0.6566
x
|
0.994
x
|
0.9115
x
|
0.3872
x
|
Free Cash Flow
1 |
22,573
|
15,043
|
21,798
|
10,273
|
8,717
|
26,784
|
ROE (net income / shareholders' equity)
|
15%
|
18.9%
|
13.6%
|
9.78%
|
11%
|
18.8%
|
ROA (Net income/ Total Assets)
|
7.37%
|
9.24%
|
11.9%
|
8.19%
|
7.17%
|
7.58%
|
Assets
1 |
214,731
|
237,321
|
145,874
|
157,733
|
208,729
|
371,180
|
Book Value Per Share
2 |
6,900
|
7,744
|
8,367
|
8,492
|
9,063
|
10,294
|
Cash Flow per Share
2 |
807.0
|
623.0
|
164.0
|
318.0
|
253.0
|
1,306
|
Capex
1 |
10,042
|
8,092
|
15,931
|
18,976
|
8,079
|
8,153
|
Capex / Sales
|
6.47%
|
4.75%
|
8.68%
|
11.17%
|
4.28%
|
3.94%
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/25/21
|
3/28/22
|
3/21/23
|
3/14/24
|
|
1st Jan change
|
Capi.
|
---|
| -7.69% | 132M | | +54.61% | 815B | | +44.25% | 654B | | -6.33% | 354B | | +20.62% | 337B | | +10.44% | 302B | | +18.45% | 247B | | +2.09% | 229B | | +13.03% | 219B | | +8.61% | 171B |
Other Pharmaceuticals
|